These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37869904)

  • 1. Kidney Intrinsic Mechanisms as Novel Targets in Renovascular Hypertension.
    Eirin A; Chade AR; Lerman LO
    Hypertension; 2024 Feb; 81(2):206-217. PubMed ID: 37869904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergent players in renovascular disease.
    Barsom SH; Glasstetter LM; Siddiqi S; Rajagopalan KS; Eirin A; Lerman LO
    Clin Sci (Lond); 2022 Feb; 136(3):239-256. PubMed ID: 35129198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic strategies for renovascular disease.
    Eirin A; Textor SC; Lerman LO
    Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):383-389. PubMed ID: 31045658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease.
    Chade AR; Krier JD; Rodriguez-Porcel M; Breen JF; McKusick MA; Lerman A; Lerman LO
    Am J Physiol Renal Physiol; 2004 Jun; 286(6):F1079-86. PubMed ID: 14722019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endovascular management of atherosclerotic renovascular disease: early results following primary intervention.
    Corriere MA; Pearce JD; Edwards MS; Stafford JM; Hansen KJ
    J Vasc Surg; 2008 Sep; 48(3):580-7; discussion 587-8. PubMed ID: 18727962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease.
    Chade AR; Tullos N; Stewart NJ; Surles B
    J Am Soc Nephrol; 2015 May; 26(5):1071-80. PubMed ID: 25377076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts.
    Pappaccogli M; Robberechts T; Lengelé JP; Van der Niepen P; Sarafidis P; Rabbia F; Persu A
    Hypertension; 2023 Jun; 80(6):1150-1161. PubMed ID: 36919595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease.
    Kelsen S; Hall JE; Chade AR
    Am J Physiol Renal Physiol; 2011 Jul; 301(1):F218-25. PubMed ID: 21478482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renovascular disease in older adults.
    Herrera AH; Davidson RA
    Clin Geriatr Med; 1998 May; 14(2):237-54. PubMed ID: 9536103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renovascular Hypertension.
    Herrmann SM; Textor SC
    Endocrinol Metab Clin North Am; 2019 Dec; 48(4):765-778. PubMed ID: 31655775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective improvement in renal function preserved remote myocardial microvascular integrity and architecture in experimental renovascular disease.
    Urbieta-Caceres VH; Zhu XY; Jordan KL; Tang H; Textor K; Lerman A; Lerman LO
    Atherosclerosis; 2012 Apr; 221(2):350-8. PubMed ID: 22341593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insights Into Pathophysiology, Diagnosis, and Treatment of Renovascular Hypertension.
    Samadian F; Dalili N; Jamalian A
    Iran J Kidney Dis; 2017 Mar; 11(2):79-89. PubMed ID: 28270639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cells and chronic renal artery stenosis.
    Oliveira-Sales EB; Boim MA
    Am J Physiol Renal Physiol; 2016 Jan; 310(1):F6-9. PubMed ID: 26538439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Concepts in the Treatment of Renovascular Hypertension.
    Herrmann SM; Textor SC
    Am J Hypertens; 2018 Jan; 31(2):139-149. PubMed ID: 28985335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherosclerotic renovascular disease among hypertensive adults.
    Davis RP; Pearce JD; Craven TE; Moore PS; Edwards MS; Godshall CJ; Hansen KJ
    J Vasc Surg; 2009 Sep; 50(3):564-570, 571.e1-3; discussion 571. PubMed ID: 19700093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.
    Tullos NA; Stewart NJ; Davidovich R; Chade AR
    Nephrol Dial Transplant; 2015 Apr; 30(4):584-93. PubMed ID: 25438341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH).
    Sarafidis PA; Theodorakopoulou M; Ortiz A; Fernandez-Fernández B; Nistor I; Schmieder R; Arici M; Saratzis A; Van der Niepen P; Halimi JM; Kreutz R; Januszewicz A; Persu A; Cozzolino M
    Nephrol Dial Transplant; 2023 Nov; 38(12):2835-2850. PubMed ID: 37202218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidant intervention blunts renal injury in experimental renovascular disease.
    Chade AR; Rodriguez-Porcel M; Herrmann J; Zhu X; Grande JP; Napoli C; Lerman A; Lerman LO
    J Am Soc Nephrol; 2004 Apr; 15(4):958-66. PubMed ID: 15034098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous revascularization for ischemic nephropathy: the past, present, and future.
    Textor SC; Misra S; Oderich GS
    Kidney Int; 2013 Jan; 83(1):28-40. PubMed ID: 23151953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis and management of renovascular hypertension and ischemic nephropathy.
    Yerram P; Karuparthi PR; Chaudhary K
    Minerva Urol Nefrol; 2012 Mar; 64(1):63-72. PubMed ID: 22402318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.